BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Curative but Unaffordable: Gene and Cell Therapy's Access Paradox in Asia

At almost every cell-and-gene-therapy conference in the region, the same slide appears: a child who was dying of leukaemia, now in durable remission; a tee...

June 03, 2026 | Analysis

Innovation Powerhouse or Inflated Bubble? Reading China’s First-in-Class Boom

A decade ago, the phrase “Chinese first-in-class drug” would have drawn a raised eyebrow in any Western boardroom. China made generics, copied ...

June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com

When America Builds a Wall: Who Inherits China’s Displaced Biotech Work?

When President Trump signed the FY2026 National Defense Authorization Act on December 18, 2025, the biopharmaceutical industry finally got the law it had s...

June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com

Engineering Precision In Chromatography From Development To Commercial Scale

Chromatography in Bioprocessing For pilot and commercial purification of monoclonal antibodies and recombinant proteins, chromatography remains the centra...

April 24, 2026 | Analysis

PFAS Testing Enters A New Era As Solvent Purity And Analytical Discipline Redefine Data Integrity

PFAS analysis has moved from a specialist capability to a core requirement for environmental control and testing laboratories because regulatory values are...

April 21, 2026 | News

Taiwan Strengthens Its Position In Asia’s Next Phase Of Bioprocessing Growth

Taiwan’s bioprocessing and biotechnology sector has moved from a predominantly research-and-services footing toward a more industrialised, globally c...

March 20, 2026 | Analysis

2026: AI Transforms China’s Pharma Sector and Drives More Strategic M&A Deals

The preceding decade was marked by rapid growth and robust policy backing; however, the landscape has fundamentally evolved. Research and development expen...

March 13, 2026 | Opinion | By By Adam Zhang Yu, Founder & CEO, Collabrium Partners

Turning Frontline Reality Into Policy Action For Cancer Care In Asia

Drawing on her frontline clinical experience in Malaysia, Prof Dr Wan Zamaniah, Consultant Clinical Oncologist, University Malaya Medical Centre&...

February 02, 2026 | Expert Insight

From Capacity to Capability: How 2026 can be the catalyst for what APAC’s Biopharma Growth Needs Next

Beyond Scale: What Will Sustain APAC’s Biopharma Leadership Asia-Pacific’s rise in global biopharma is no longer about whether the region can ...

January 21, 2026 | News | By Joonho Choi, Vice President, Asia-Pacific, Cytiva

26 Key Trends Shaping Biotech And Life Sciences In 2026

As 2026 unfolds, biotech and life sciences are moving into a phase defined less by promise and more by execution. Faster R and D cycles, smarter cl...

January 05, 2026 | News

BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025

The year 2025 has marked a pivotal moment for the biopharmaceutical industry as it reckons with the aftershocks of a global pandemic and ongoing geopolitic...

December 24, 2025 | Analysis

Building Trust Through Quality: How QMS Powers Manufacturing Excellence in Life Sciences

Life sciences sector, a robust Quality Management System (QMS) has become the cornerstone of manufacturing excellence. This is especially true for the medi...

October 16, 2025 | Analysis

Turning Signals into Cures: The Big Data Blueprint for Cell Therapy Factories

Cell therapy manufacturing is entering a data-driven era, as the industry grapples with complex production processes, high costs, and the need for personal...

October 07, 2025 | Analysis

Takeda Steps Back from Cell & Gene Therapy to Refocus on Predictable Growth

Takeda Pharmaceutical, one of the world’s most globalised pharma companies, has confirmed it will step away from in-house development of its cell and...

October 05, 2025 | News

Stay Connected